ONC201 in Gliomas

ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) that is able to penetrate the blood-brain-barrier effectively. ONC201’s DRD2 antagonism engages proven anti-cancer pathways that lead to apoptosis in cancer cells. Oncoceutics has completed a successful Phase I study with ONC201 in solid tumors and has additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies ongoing.

Based on clinical results indicating that ONC201 is effective against gliomas with the H3 K27M mutation, Oncoceutics has launched Phase II clinical trials targeting H3 K27M-mutant gliomas.

Objective Response in Patient with Recurrent Glioblastoma after 12 Cycles of ONC201 Therapy (36 Weeks)

Source: Arrillaga-Romany, et al., A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma”, Oncotarget. 2017; 8:79298-79304. https://doi.org/10.18632/oncotarget.17837

Clinical Trials for ONC201 in H3 K27M-mutant Gliomas

Oncoceutics is currently enrolling adult patients with the H3 K27M mutation in Phase II studies at NYU Langone and at the Massachusetts General Hospital and pediatric patients in a Phase I study at the Stephen D. Hassenfeld Childrens Center for Cancer and Blood Disorders at NYU Langone.